GlassScriptPhysician profile
Tarun Bhandari
NPI 1437382470
$13,270.27
in general payments reported to CMS, 2019-2025
29 companies · $2,601 in 2025
The $2,601 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,652 · 2020: $1,125 · 2021: $2,232 · 2022: $1,787 · 2023: $1,777 · 2024: $2,096 · 2025: $2,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,393 · Education: $80.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,392.66 |
| Education | $80.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,941.88 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $1,465.49 | 2019-2025 | Rexulti |
| Alkermes, INC. | $1,447.59 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $1,169.81 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Abbvie INC. | $1,108.41 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $958.41 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $745.20 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $649.46 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $579.57 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $562.90 | 2019-2023 | Trintellix, Rixubis |
| Sunovion Pharmaceuticals INC. | $516.15 | 2019-2022 | |
| Corium, LLC | $410.26 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $382.24 | 2019-2025 | Wellbutrin, Aplenzin |
| Vanda Pharmaceuticals INC. | $325.33 | 2019-2025 | Fanapt |
| Allergan, INC. | $165.20 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $157.88 | 2021-2024 | Qelbree |
| Tris Pharma INC | $120.42 | 2019-2024 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $111.19 | 2019-2021 | |
| Neuronetics, INC. | $98.93 | 2022 | |
| Shire North American Group INC | $83.33 | 2019 | |
| Neos Therapeutics, LP | $73.64 | 2019 | |
| Ironshore Pharmaceuticals INC. | $38.04 | 2019 | |
| Eisai INC. | $33.29 | 2021 | |
| Almatica Pharma LLC | $30.63 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $29.24 | 2019-2020 | |
| Angiodynamics, INC. | $18.46 | 2020 | |
| Merck Sharp & Dohme LLC | $18.39 | 2021 | |
| W. L. Gore & Associates, INC. | $15.08 | 2019 | |
| Biogen, INC. | $13.85 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarun Bhandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.